Tracer library / [90Y]Y-90-NM600
[90Y]Y-90-NM600
Also written as Y-90-NM600
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- NM600 (alkylphosphocholine analog)
- Target / mechanism
- —
- Clinical application
- Metastatic prostate cancer and various tumor types treated with targeted radionuclide therapy, often combined with immunotherapy PMID 36002185
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | SPE | — | >95% | NM600 Archeus Technologies | 38663936 2024 J Immunother Cancer |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Archeus Technologies
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [90Y]Y-90-NM600, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38663936: 'Clinical grade 90YCl3 and NM600 were obtained from PerkinElmer (Shelton, CT) and Archeus Technologies (Madison, WI) respectively.'. Stage set/updated at stage 39 from PMID 34383787: 'Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors.'.